Latham & Watkins Advises Parvus Therapeutics on Collaboration With AbbVie

Parvus Therapeutics has announced that it has entered into an exclusive worldwide license collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) for the development and commercialization of novel treatments for Inflammatory Bowel Disease (IBD), utilizing Parvus’ Navacim™ Treg immune tolerization platform technology. Navacims™ present multivalent peptide major histocompatibility complexes (peptide-MHCs) to T cells, triggering the endogenous expansion and differentiation of the T cells into antigen-specific Tregs. This approach is being evaluated as a potential to halt or cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immunity.

Latham & Watkins advised Parvus on the agreement, with a team led by Bay Area partner Judith Hasko, with associates Robert Yeh and Xiaohan (Billy) Wu. Advice was also provided on corporate matters by Bay Area partner Ben Potter; on FDA matters by Washington, D.C. partner Elizabeth Richards; on tax matters by Bay Area partner Kirt Switzer, with associate Greg Conyers; on data privacy matters by Bay Area partner Heather Deixler, with associate Oliver Mobasser; on antitrust matters by Washington, D.C. partner Peter Todaro; and on anti-corruption and compliance matters by New York partner Matthew Salerno.